Immunogenicity and efficacy of Hoshino strain of mumps vaccine in Iran; two years study.

Authors:
Address: Dept. of Infectious and Tropical Diseases and Iranian Traditional Medicine Research Centre, Isfahan University of Medical Sciences, Isfahan, Islamic Republic of Iran. avijgan@yahoo.com
Journal:

Publication:

abstract

This report describes the Immunogenicity and efficacy and long term immunity of Hoshino strain of mumps (included in MMR vaccine) in shahr-e-kord, Islamic Republic of Iran (I.R.Iran). A total of 338 Children aged 3-18 years were tested for Mumps IgG using enzyme-linked immunosorbent assay (ELISA). The proportion of susceptible, mumps IgG negative, children was 19.8% (67 subjects). Of the 67 susceptible children, 36 received the MMR vaccination and successfully completed the study. Blood was collected by venipuncture 3, 12, and 24 months after vaccination and serum samples were tested by ELISA for detection of Mumps IgM and IgG. The overall seroconversion rate was 86.1%, 77.7% and 75% at 3, 12, and 24 months after vaccination respectively.

Related Articles
Measles-mumps-rubella revaccination; 18 months vs. 4-6 years of age: potential impacts of schedule changes.
J Trop Pediatr. 2011
Measles-mumps-rubella revaccination; 18 months vs. 4-6 years of age: potential impacts of schedule changes.
Saffar MJ, Fathpour GR, Parsaei MR, Ajami A, Khalilian AR, Shojaei J, Saffar H. J Trop Pediatr. 2011 Oct; 57(5):347-51. Epub 2010 Nov 14.
Open randomized trial comparing the immunogenicity and safety of a new measles-mumps-rubella vaccine and a licensed vaccine in 12- to 24-month-old children.
Pediatr Infect Dis J. 2005
Open randomized trial comparing the immunogenicity and safety of a new measles-mumps-rubella vaccine and a licensed vaccine in 12- to 24-month-old children.
Feiterna-Sperling C, Brönnimann R, Tischer A, Stettler P, Durrer P, Gaedicke G. Pediatr Infect Dis J. 2005 Dec; 24(12):1083-8.
Immunogenicity and efficacy of one dose measles-mumps-rubella (MMR) vaccine at twelve months of age as compared to monovalent measles vaccination at nine months followed by MMR revaccination at fifteen months of age.
Vaccine. 2001
Immunogenicity and efficacy of one dose measles-mumps-rubella (MMR) vaccine at twelve months of age as compared to monovalent measles vaccination at nine months followed by MMR revaccination at fifteen months of age.
Ceyhan M, Kanra G, Erdem G, Kanra B. Vaccine. 2001 Aug 14; 19(31):4473-8.
Review Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella.
Drugs. 2003
Review Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella.
Wellington K, Goa KL. Drugs. 2003; 63(19):2107-26.
Review Evolution of surveillance of measles, mumps, and rubella in England and Wales: providing the platform for evidence-based vaccination policy.
Epidemiol Rev. 2002
Review Evolution of surveillance of measles, mumps, and rubella in England and Wales: providing the platform for evidence-based vaccination policy.
Vyse AJ, Gay NJ, White JM, Ramsay ME, Brown DW, Cohen BJ, Hesketh LM, Morgan-Capner P, Miller E. Epidemiol Rev. 2002; 24(2):125-36.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.